Food & Drug Administration (FDA) approved Faslodex, or fulvestrant, for the treatment of hormone receptor positive metastatic breast cancer in post-menopausal women whose disease progresses following anti-estrogen therapy. Way that estrogen can stimulate the growth of tumors; Effectiveness of the drug;...
Breast cancer is the most common cancer in women in the U.S., excludingskin cancers, and is the second leading cause of cancer death in women, though deaths have steadily declined due to earlier detection through screenings and better treatment options. The earlier breast cancer is detected, ...
It is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation, the FDA said on Friday. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test. "This class of drugs has been used to...
“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed therapi...
Another group's different ACSS2-inhibiting approach is inhuman clinical trials, and Schug's research shows how ACSS2-inhibiting treatment might be able to improve outcomes for patients diagnosed with the infamous TNBC. By testing ACSS2 inhibitors alongside standard anti-breast-cancer chemotherapy, Sch...
These findings suggest promising treatment options while raising important questions about which subgroups would benefit most. Dr Armaghani notes that the discussions and questions sparked by these studies are expected to continue and evolve.
In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma. Image credit: freshidea | stock.adobe.com During a presentation at the National Comprehensive Cancer Network Annual 2024 Conference in Orlando, ...
Breast cancer is the second most common cancer among U.S. women behind skin cancer. Death rates from breast cancer have decreased steadily in the past three decades because of earlier diagnoses through screening and increased awareness, along with improvements in cancer treatment. However, Black wom...
Approximately 10 to 15 percent of breast cancer cases do not respond to treatment with hormone therapy, which means that they are more aggressive and often recur. An international research team led by researchers at Lund University in Sweden has uncovere
Scientists at the MedUni Vienna, in collaboration with a working group led by Nancy Hynes at the University of Basel, have discovered a new approach in the treatment of breast cancer: an international team involving the Clinical Institute of Pathology at